Since TFEB activity stimulates autophagy and lysosomal activity, among other functions, if targeted dephosphorylation of TFEB leads to its activation, then it could offer a promising innovative strategy for therapeutic targeting against lysosomal-related diseases, such as neurodegenerative diseases, cystinosis, acute kidney injury, and diabetic nephropathy. The gene discussed is TFEB; the disease is acute kidney injury.